Next Article in Journal
Enhanced Adsorption of Bromoform onto Microplastic Polyethylene Terephthalate Exposed to Ozonation and Chlorination
Next Article in Special Issue
Electrochemical Characterization of the Antioxidant Properties of Medicinal Plants and Products: A Review
Previous Article in Journal
Monitoring and Exposure Assessment of Fosetyl Aluminium and Other Highly Polar Pesticide Residues in Sweet Cherry
Previous Article in Special Issue
Response Surface Modeling and Optimization of the Extraction of Phenolic Antioxidants from Olive Mill Pomace
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 1
10.3390/molecules28010258
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Medicarpin and Homopterocarpin Isolated from Canavalia lineata as Potent and Competitive Reversible Inhibitors of Human Monoamine Oxidase-B

by
Jong Min Oh
1,
Hyun-Jae Jang
2,
Myung-Gyun Kang
3,
Seul-Ki Mun
1,
Daeui Park
3,
Su-Jin Hong
2,
Min Ha Kim
4,
Soo-Young Kim
4,
Sung-Tae Yee
1 and
Hoon Kim
1,*
1
Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea
2
Natural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea
3
Department of Predictive Toxicology, Korea Institute of Toxicology, Daejeon 34114, Republic of Korea
4
National Institute of Biological Resources, Environmental Research Complex, Incheon 22689, Republic of Korea
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(1), 258; https://doi.org/10.3390/molecules28010258
Submission received: 17 November 2022 / Revised: 13 December 2022 / Accepted: 21 December 2022 / Published: 28 December 2022
(This article belongs to the Special Issue Natural Products from Plant: From Determination to Application)
Browse Figures
Review Reports Versions Notes

Abstract

:
Thirteen compounds were isolated from the Canavalia lineata pods and their inhibitory activities against human monoamine oxidase-A (hMAO-A) and -B (hMAO-B) were evaluated. Among them, compounds 8 (medicarpin) and 13 (homopterocarpin) showed potent inhibitory activity against hMAO-B (IC50 = 0.45 and 0.72 µM, respectively) with selectivity index (SI) values of 44.2 and 2.07, respectively. Most of the compounds weakly inhibited MAO-A, except 9 (prunetin) and 13. Compounds 8 and 13 were reversible competitive inhibitors against hMAO-B (Ki = 0.27 and 0.21 µM, respectively). Structurally, the 3-OH group at A-ring of 8 showed higher hMAO-B inhibitory activity than 3-OCH3 group at the A-ring of 13. However, the 9-OCH3 group at B-ring of 13 showed higher hMAO-B inhibitory activity than 8,9-methylenedioxygroup at the B-ring of 12 (pterocarpin). In cytotoxicity study, 8 and 13 showed non-toxicity to the normal (MDCK) and cancer (HL-60) cells and moderate toxicity to neuroblastoma (SH-SY5Y) cell. Molecular docking simulation revealed that the binding affinities of 8 and 13 for hMAO-B (−8.7 and −7.7 kcal/mol, respectively) were higher than those for hMAO-A (−3.4 and −7.1 kcal/mol, respectively). These findings suggest that compounds 8 and 13 be considered potent reversible hMAO-B inhibitors to be used for the treatment of neurological disorders.

1. Introduction

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in the elderly, regardless of gender, race, or social status, and affects about 1.5 to 2.0% of people over 60 years of age and 4% of people over 80 years of age [1]. The main cause of PD is loss of dopaminergic neurons in the substantia nigra, and PD patients show major motor symptoms such as tremor and stiffness along with anxiety, depression, and dementia. Increasing dopamine (DA) level and targeting the DA-related serotonin system have been expected as anticipating areas for the treatment of PD [2]. DA levels within substantia nigra pars compacta (SNpc) neurons are maintained through synthesis of DA, synaptic vesicle loading, uptake from the extracellular space, and catabolic degradation. DA catabolism, on the other hand, begins with oxidative deamination, a reaction mediated by mitochondrial monoamine oxidase (MAO, EC 1.4.3.4) that also produces H2O2 and ammonia [3]. Therefore, increasing the concentration of DA through MAO inhibitors can be expected to relieve the symptoms by maintaining the lost DA concentration in PD patients.
Alzheimer’s disease (AD), a leading cause of dementia, is a progressive neurodegenerative disease [4]. AD affects more than 50 million people, and its main symptoms are memory and cognitive declines [5]. Various inhibitors have been being studied for the drugs of AD treatment. As one of the inhibitors, MAO inhibitors are used to treat neurological and psychiatric disorders by increasing levels of neurotransmitter such as DA, serotonin (or 5-hydroxytryptamine, 5-HT), and norepinephrine, thereby reducing MAO activity, which can cause neurological disorders [6]. On the other hand, cholinesterase (ChE) inhibitors have been studied as important tools for the treatment of AD. Acetylcholine (ACh) is a neurotransmitter in the central and peripheral nervous systems, and thus, a decrease in ACh by acetylcholinesterase (AChE) has been identified as a major cause of AD, and therefore many researches about ChE inhibitors are ongoing [7]. In addition, aggregation of beta-amyloid (Aβ) produced by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) was also studied as a cause of AD [8,9].
More specifically, MAO catalyzes the oxidative deamination of monoamines during neurotransmission with two isoforms, namely, MAO-A and MAO-B, in mitochondrial outer membranes [10]. MAO is a pharmacological target because it is involved in catecholamine and 5-HT inactivation pathways. In fact, selective reversible inhibitors of MAO-A have been targeted for anti-depression treatment, while selective reversible inhibitors of MAO-B are targets of therapeutic agents for AD and PD. Typically, selegiline, rasagiline, pargyline, and clorgyline are used as selective MAO inhibitors to reduce the symptoms of neurodegenerative and neurological diseases [11,12]. On the other hand, it was reported that MAO is also associated with the formation of amyloid plaques, which is a main cause of AD [13]. In addition, serious side effects of non-selective MAO inhibitors have been reported [14]. For this reason, selective MAO-B inhibitors based on diverse scaffolds have been actively researched (for reviews see [15,16,17]) and recently reported [18,19].
AChE (EC 3.1.1.7) shows therapeutic efficacy by increasing synaptic ACh levels in the cerebral cortex of AD patients, thereby improving cholinergic transmission [20]. As an AChE inhibitor, tacrine was used as a first drug for AD treatment. However, tacrine has been found to have a severe hepatotoxicity and is not currently used. Since then, donepezil, rivastigmine, and galantamine have been used as AChE inhibitors for therapeutic agents [11]. Like AChE, butyrylcholinesterase (BChE) is a serine hydrolase that rapidly affects the hydrolysis of the neurotransmitter ACh. The main catalytic activity of BChE is the hydrolysis of the neurotransmitters such as ACh and butyrylcholine (BCh) with a preference of BCh [21,22]. BChE is also involved in the development of the nervous system, detoxification, hydrolysis of drugs such as cocaine, heroin and aspirin, fat metabolism, and the interaction and functional modification of other proteins such as polyproline and trypsin [23]. In addition, inhibition of BACE1 related to the accumulation of Aβ for the treatment of AD patients is regarded as one of the important factors. Although many studies about BACE1 inhibitors have been reported, no one has been successful [24]. However, recently aducanumab is found to be effective to reduce Aβ plaques approved as a drug for AD by FDA [25]. Therefore, it is judged that BACE1 inhibitors are deserved to be extensively studied to reduce Aβ plaques.
Furthermore, multitargeting therapeutic strategies have been developed to target MAO-B, AChE, and/or BACE1 [26,27]. It has been reported MAO and AChE inhibitors may improve cognitive functions and alleviate symptoms in AD by elevating levels of monoamines and choline esters [28,29].
During our on-going efforts to identify potent compounds in an herbal extract library, rhamnocitrin isolated from the leaves of Prunus padus var. seoulensis was found to potently and selectively inhibit human MAO-A (hMAO-A) [30], and calycosin and 8-O-methylretusin isolated from Maackia amurensis were identified as selective human MAO-B (hMAO-B) inhibitors [31]. In addition, ellagic acid isolated from Castanopsis cuspidata var. sieboldii showed inhibition of hMAO-B and BACE1 as a multi-target inhibitor [32].
Canavalia lineata is a tendril perennial plant that blooms from June to August and bears fruit in October, rarely growing on the beach. C. lineata grows on Jeju Island in Korea and is also distributed in China, Japan, and Taiwan. It is mainly used as feed for livestock, but because of its toxicity, it was also used for abortion in the past [33]. A few physiological activities of C. lineata have been reported about anti-inflammation [34], and proteinase inhibition [35]. However, no study has been reported about MAO inhibitory activity of C. lineata. In the present study, we isolated thirteen compounds from the pods of C. lineata by activity-guided screening for hMAO inhibition, and evaluated their inhibitory effects on hMAO-A, hMAO-B, AChE, BChE, and BACE1, including kinetic studies and molecular docking simulation.

2. Results and Discussion

2.1. Preparation and Identification of Compounds 1–13

Constituents in C. lineata pod MeOH extract were separated by reverse phase column chromatography as described previously [34]. Compounds were purified by bioactivity-guided fractionation using MPLC for EtOAc and BuOH fractions and HPLC for their sub-fractions (Figure S1). Phytochemicals profile analysis of the C. lineata pod extract was carried out using UPLC-QTOF/MS and -PDA (Figure S2). Structures of the compounds isolated were elucidated by comparison with NMR and MS data (Figures S3–S15) as rutin (1), (2R,3R)-3-hydroxy-7-O-β-D-glucopyranoside-6-methoxyflavanone (2), (–)-syringaresinol-4-O-β-D-glucopyranoside (3), ononin (4), (+)-syringaresinol (5), (2R,3R)-3,7-dihydroxy-6-methoxyflavanone (6), cajanin (7), medicarpin (3-hydroxy-9-methoxypterocarpan, 8), prunetin (9), 7,4′-dimethyl-3′-hydroxygenistein (10), 7,4′-dimethoxyisoflavone (11), pterocarpin (3-methoxy-8,9-methylenedioxypterocarpan, 12), and homopterocarpin (3,9-dimethoxypterocarpan, 13) (Figure 1). Compounds 6 (a flavonoid, 15.4 mg), 8 (a pterocarpan, 22.5 mg), and 13 (a pterocarpan, 31.9 mg) were detected as major metabolites of C. lineata pods. Compounds 8 and 13 were pterocarpans, derivatives of the isoflavonoid.

2.2. MAO Inhibitory Activities

A primary screening for MAO inhibition was performed using MeOH extract of C. lineata pods, and its EtOAc and BuOH fractions. The MeOH extract showed high MAO-B inhibition with residual activity of 53.5%. However, inhibition of MAO-A, AChE, BChE, and BACE1 inhibitions were weak (residual activities of 76.1, 78.2, 98.9, and 76.1%, respectively). After second additional extraction, MAO-B residual activity of EtOAc fraction (41.4%) was higher than that of BuOH fraction (85.9%) (Table 1). During the isolation of compounds from the extracts, thirteen compounds were identified and evaluated for their hMAO-A, hMAO-B, AChE, BChE, and BACE1 inhibitory activities. Four compounds showed MAO-A residual activities of less than 50%, and two compounds showed MAO-B residual activities of less than 10% (Table 2). In IC50 determination, compound 8 (medicarpin) showed the highest inhibitory activity against MAO-B with an IC50 value of 0.45 µM (Table 2, Figure S16), followed by 13 (homopterocarpin, IC50 = 0.72 µM) (Table 2, Figure S17). However, compound 12 (another pterocarpan) showed 7.47 times lower MAO-B inhibition (IC50 = 3.36 µM) than compound 8. Compound 13 showed highest MAO-A inhibitory activity with an IC50 value of 1.49 µM, followed by 9 (prunetin, IC50 = 2.49 µM). Other compounds showed higher IC50 values for MAO-A, near 10 µM. Regarding selectivity index (SI), compounds 8 and 13 had selectivity index (SI) values of 44.2 and 2.07 for MAO-B over MAO-A, respectively (Table 2). However, most of the compounds showed low inhibitory activity against AChE, BChE, and BACE1 (Table 1).
Regarding structure–activity relationships (SAR) for hMAO-B inhibitory activities, 3-OH group at A-ring of 8 showed 1.6 times higher hMAO-B inhibitory activity than 3-OCH3 group at the A-ring of 13. However, 9-OCH3 group at B-ring of 13 showed 4.7 times higher hMAO-B inhibitory activity than 8,9-methylenedioxy group at the B-ring of 12 (pterocarpin) (Table 2, Figure 2). Interestingly, compound 8 exhibited similar, but slightly higher (1.5 times) hMAO-B inhibition than maackiain, containing 8,9-methylenedioxy group (IC50 = 0.68 µM [36]) (Figure 2). When comparing 12 to maackiain, 3-OCH3 group instead of 3-OH group at the A-ring decreased hMAO-B inhibition but increased hMAO-A inhibition, and, additionally, 4-OH group at the A-ring of 4-hydroxy-3-methoxy-8,9-methylenedioxypterocarpan (HMMDP) [36] decreased hMAO-B inhibition as well as hMAO-inhibition.
These inhibitory activities of 8 and 13 were similar to that of an isoflavone calycosin (0.24 µM) [31], flavones acacetin (0.17 µM) [37] and acacetin 7-methyl ether (0.20 µM) [38], a pterocarpan maackiain (0.68 µM) [36], an isoflavone genistein (0.65 µM) [39]. On the other hand, 8 has been reported to have efficacy in the recovery of memory loss in scopolamine-induced mice [40], antioxidant [41], and protection of cerebral microvascular endothelial cells [42], and anti-cancer [43]. In addition, compound 13 (homopterocarpin) has been reported to have anti-cancer [44], hepatoprotective [45] and antioxidant effects [45].

2.3. Analysis of the Reversibility of hMAO-A and hMAO-B Inhibitions

Reversibilities of hMAO-A and hMAO-B inhibitions by compounds 8 and 13 were investigated by dialysis. Inhibition of hMAO-A by 13 was substantially recovered from 25.4% (AU) to 75.8% (AD), and these values by 13 were similar to those by the reversible inhibitor toloxatone (22.7 to 84.6%). Little recovery was observed for the irreversible inhibitor clorgyline (23.7 to 32.1%) (Figure 3). Inhibitions of hMAO-B by 8 and 13 were substantially recovered from 29.8% (AU) to 72.7% (AD), and from 32.0% to 73.5%, respectively, and these values were similar to those observed for the reversible inhibitor lazabemide (31.6 to 83.3%) (Figure 4). Besides, the irreversible inhibitor pargyline did not show activity recovery at all (34.4 to 29.1%). These results indicated compound 8 was a reversible inhibitor of hMAO-B and 13 was a reversible inhibitor of hMAO-A or hMAO-B.

2.4. Analysis of Inhibitory Patterns

Enzyme kinetics of compounds 8 and 13 were investigated using Lineweaver–Burk plots. Plots of hMAO-B inhibition by 8 were linear and intersected the y-axis (Figure 5A,B), indicating compound 8 is a competitive inhibitor of MAO-B. Secondary plots of the slopes of Lineweaver–Burk plots against inhibitor concentration showed the Ki value of 8 was 0.197 ± 0.004 µM (Figure 5B). Similarly, compound 13 was found to be a competitive inhibitor of hMAO-A or hMAO-B with Ki values of 0.617 ± 0.023 (Figure 6A,B) and 0.212 ± 0.008 µM (Figure 6C,D), respectively. These Ki values of 8 and 13 for MAO-B were slightly higher than those of the potent fluorinated chalcones f1 and f2 (0.027 and 0.020 µM, respectively) [46], 1-methyl, 5-phenyl substituted thiosemicarbazones MT5 (6.58 µM) [47]. These results indicate compounds 8 was a potent competitive inhibitor of hMAO-B and compound 13 was an effective competitive inhibitor of hMAO-A and a more effective competitive inhibitor of hMAO-B.

2.5. Cytotoxicity Test

The effects of 8 and 13 on the viabilities of MDCK, HL-60, and SH-SY5Y cells were investigated using the CCK-8 assay. Compounds 8 and 13 showed no effects on the viabilities of MDCK (normal cell line) or HL-60 (cancer cell line) cells at 50 µM, the highest concentration tested (Figure 7A,B). However, 8 and 13 showed moderate toxicity (74.05% and 71.12% viability, respectively) to SH-SY5Y (neuroblastoma) cells at 30 µM, which is 66.7- and 41.7-times higher, respectively, than IC50 values of 8 and 13 (Figure 7C). These results suggest that 8 and 13 are non-toxic to the cells tested with a moderate toxicity to SH-SY5Y cells.

2.6. Molecular Docking Simulation

Major compounds 8 and 13, two pterocarpans, were docked to hMAO-A and hMAO-B. Compound 12 was also included in docking simulation, because it was a pterocarpan derivative, though it was not a potent hMAO-B inhibitor. The docking simulations showed that the chemicals were located properly within the active region of hMAO-A (PDB: 2Z5X) and hMAO-B (PDB ID:4A79) (Figure 8). The compounds were docked in similar locations hMAO-A or hMAO-B, based on the surrounded amino acid residues: the compounds were located near FAD cofactor in hMAO-A, whereas they were located far from the FAD site (Figure 8). Three compounds showed higher binding affinities to hMAO-B than hMAO-A, representing they are selective hMAO-B inhibitor. Compound 8 showed the highest binding affinity (−8.7 kcal/mol) for hMAO-B as compared to other docking complexes, and formed a hydrogen bond interaction with Cys172 residue at a distance of 3.328Å (Figure 8A,B, Table 3). Compound 13 also displayed similar results, but relatively lower binding affinities for both of MAO-A (−7.1 kcal/mol) and hMAO-B (−7.7 kcal/mol) by hydrogen bond interactions with Tyr444 (hMAO-A at a distance of 3.588 Å) and Cys172 (hMAO-B at a distance of 3.333 Å), respectively (Figure 8E,F, Table 3). Compound 12, which differs in only substituent of the B-ring of compound 13, was predicted to have no hydrogen bond interaction with hMAO-A and hMAO-B and showed lower binding affinities (−2.4 and −7.5 kcal/mol, respectively) to both hMAO-A and hMAO-B than 8 and 13 (Figure 8C,D, Table 3). hMAO-B has relatively narrow ‘gate’ (defined by Ile199 and Tyr326) in the cavity, although hMAO-B has high sequence identity ≥70% to hMAO-A [48]. In this aspect, it might be suggested that 3-hydroxy group in 8 was more favored to hMAO-B than 3-methoxy group in 13, and 8,9-methylenedioxy group in 12 decreased the affinity to hMAO-B compared to 9-methoxy group in 8 and 13 (Figure 8C,D). In addition, docking scores using AutoDock Vina are calculated based on considerations of various factors such as hydrogen bonding, electrostatic bonding, van der Waals forces, and dissolvent effects [49]. These scores obtained in this study were coincided well to the IC50 values of the compounds determined experimentally. These results suggest that compound 8 would be the most selective inhibitor against hMAO-B and compound 13 have effective inhibition activity against both hMAO-A and hMAO-B.

2.7. In Silico Pharmacokinetics of Medicarpin (8) and Homopterocarpin (13)

The pharmacokinetics of compounds 8 and 13 using SwissADME web tool showed these two compounds had high GI absorption and BBB permeability (Table 4). However, drug suitability of two compounds should be investigated in further study, because these compounds showed CYP450 inhibition including the important enzyme CYP3A4, although cytotoxicity to three cell lines tested above was low and some of the drugs show CYP3A4 inhibition properties [50]. Lipinski violation is judged by counting the number of violations in the Lipinski’s rule, i.e., MW < 500, cLog Po/w < 5.00, HBD < 5, HBA < 10, TPSA < 140 Å2, and RB < 10. For Lipinski parameters of these two compounds, no violations of Lipinski’s rule of five were predicted (Table 5). These results suggest that compounds 8 and 13 can used as central nervous system (CNS) drugs.

3. Materials and Methods

3.1. General Experimental Procedures

NMR spectroscopic data were recorded by using JEOL ECZ500R [1H NMR at 500 MHz, 13C NMR at 125 MHz, (JEOL, Tokyo, Japan)] and Bruker AVANCE III HD 700 [1H NMR at 700 MHz, 13C NMR at 175 MHz, (Bruker, Billerica, MA, USA)] instruments. High-resolution electrospray ionization mass (HR-ESI-MS) data were obtained using a Vion ion mobility spectroscopy-quadrupole time-of-flight (IMS-QTOF) and ACQUITY ultra-performance liquid chromatography (UPLC) I-Class (Waters, Milford, MA, USA) system coupled with ACQUITY BEH C18 column (Waters). Optical rotation and CD spectra were recorded on a Jasco P-1000 polarimeter and J-815 spectrometer (Jasco, Tokyo, Japan), respectively. Medium-pressure liquid chromatography (MPLC, Spot Prep II System, Armen, Paris, France), preparative HPLC (Gilson PLC 2020 system, Gilson, Middleton, WI, USA), and multiple preparative HPLC (LC-Forte/R, YMC, Kyoto, Japan) were applied to obtain phytochemicals from C. lineata pod MeOH extract using C18 columns, YMC-Triart C18 ExRS (20.0 × 250 mm, 10 µm, YMC) and YMC ODS-AQ (20.0 × 250 mm, 10 µm, YMC).

3.2. Plant Materials and Preparation of Compounds 1–13

The plant materials were collected from Gujwa-eup, Jeju-do, Republic of Korea, in 2019. C. lineata was authenticated by National Institute of Biological Resources (NIBR, Dr. Min Ha Kim) and a voucher specimen (NIBRVP0000634114) was deposited at NIBR. In the previous study, the preparation of C. lineata pods extracts and the identification of phytochemicals isolated were reported by Hong et al. [34]. Briefly, the dried C. lineata pods (1.2 kg) were extracted with methanol (MeOH) (20 L × 3 times), then the concentrated MeOH extracts (152 g) were suspended in distilled water (1 L) and partitioned sequentially into ethyl acetate (EtOAc)- and butanol (BuOH)-soluble fractions. EtOAc and BuOH fractions were isolated by the MPLC using reverse-phase open-column (YMC ODS-AQ, 10 µm, 220 g) eluting with a gradient system of a mixture H2O and MeOH (5–100% MeOH, 50 mL/min) to yield 30 (CLPE1–CLPE30) and 25 fractions (CLPB1–CLPB25), respectively. Compounds 2 and 4–13 were purified from EtOAc sub-fractions (CLPE9, 14, 18, 21, 22, 24, 27, 28, and 30) using the preparative HPLC (YMC-Triart C18 ExRS, YMC). The preparative HPLC (YMC ODS-AQ, YMC) was used to separate compounds 1 and 3 from BuOH sub-fractions (CLPB15 and CLPB16) (Figure S1). All isolates were identified using mass fragmentation pattern and accurate mass acquired by Waters ACQUITY UPLC system equipped with QTOF mass spectrometry (Vion IMS-QTOF/MS) with ESI source and NMR spectroscopy. UPLC chromatographic condition and mass spectrometric parameters were described by Jang et al. [51].

3.3. Chemicals and Enzymes

Recombinant hMAO-A and hMAO-B, kynuramine, benzylamine, AChE from Electrophorus electricus, BChE from equine serum, 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), acetylthiocholine iodide (ATCI), butyrylthiocholine iodide (BTCI), BACE1 activity detection kit (fluorescent) and the reversible inhibitors (toloxatone, lazabemide, donepezil, quercetin) were purchased from Sigma-Aldrich (St. Louis, MO, USA) [30,31]. The reference irreversible inhibitors (clorgyline and pargyline) were obtained from Bioassay Systems (Hayward, CA, USA) [52]. All other chemicals were of reagent grade.

3.4. Enzyme Assays

hMAO-A and -B activities were determined using a continuous spectrophotometric method, as described previously [53,54]. The Km values of hMAO-A for kynuramine and hMAO-B for benzylamine were 0.043 and 0.14 mM, respectively. The concentrations of kynuramine (0.06 mM) and benzylamine (0.3 mM) used were 1.4- and 2.1-times Km values, respectively. AChE and BChE activities were assayed as described by Ellman et al. [55], with slight modification [40]. Reactions were performed using AChE and BChE in the 0.5 mL reaction mixtures including 0.5 mM substrate (ATCI and BTCI, respectively) and color reagent (DTNB). Absorbance measurements were continuously monitored for 10 min at 412 nm. Reaction rates are expressed as changes in absorbance per min. [56]. Inhibitory activities of AChE and BChE were measured after preincubating enzyme with inhibitors for 15 min before adding DTNB and each substrate. BACE1 assay was measured by the activity detection kit using a fluorescence spectrometer (FS-2, Scinco, Seoul, Republic of Korea), for 2 h at 37 °C with 7-methoxycoumarin-4-acetyl-[Asn670, Leu671]-amyloid β/A4 protein fragment 667-676-(2,4-dinitrophenyl)Lys-Arg-Arg amide trifluoroacetate as a substrate [57].

3.5. Kinetics of Enzyme Inhibition

Inhibitions of hMAO-A, hMAO-B, AChE, BChE, and BACE1 by the thirteen compounds were initially investigated at a concentration of 10 µM, and then IC50 values of the compounds and the reference inhibitors (toloxatone and clorgyline for hMAO-A, lazabemide and pargyline for hMAO-B, donepezil for AChE and BChE, and quercetin for BACE1) were determined. Kinetic parameters, inhibition types, and Ki values of the most potent hMAO-B inhibitors (compounds 8 and 13) were analyzed, as described previously [31]. The kinetics of MAO-B inhibition by 8 and 13 were investigated at five different substrate concentrations (0.03–0.6 mM) and in the absence or presence of each inhibitor at three concentrations of ~0.5, 1.0, and 2.0 times of each IC50 value [30]. The kinetics of MAO-A inhibition by 13 was also investigated as above, except at 0.0075–0.12 mM of substrate concentrations. Inhibitory types and Ki values were determined using Lineweaver-Burk plots and secondary plots of their slopes, respectively.

3.6. Analysis of Inhibitor Reversibility

The reversibilities of hMAO-A or hMAO-B inhibitions by compounds 8 and 13 were investigated by dialysis, as previously described [53], at ~2 times of IC50 concentrations. Reversible and irreversible reference inhibitors were also included in the experiment at ~ 2 times of IC50 concentrations. After preincubating compounds or reference inhibitors with hMAO-A and hMAO-B, residual activities for undialyzed and dialyzed samples were measured. Relative values for undialyzed (AU) and dialyzed (AD) activities were then calculated and compared with non-inhibitor treated controls. Reversibilities were determined by comparing the AU and AD values of inhibitors with those of references.

3.7. Cytotoxicity

3.7.1. Reagents and Cell Lines

Dulbecco’s Modified Eagle Medium (DMEM), Roswell Park memorial Institute (RPMI) 1640, Minimum Essential Medium (MEM), Fetal Bovine Serum (FBS), Penicillin/Streptomycin solution, and Trypsin-EDTA solution were purchased from Hyclone Laboratories (Logan, UT, USA). Dimethyl sulfoxide (DMSO) and 2-mercaptoethanol (2-ME) were obtained from Sigma Aldrich. Cell counting kit-8 (CCK-8) was obtained from Dojindo Laboratories (Kumamoto, Japan). Madin-Darby canine kidney (MDCK; KCLB 10034) cells, human acute promyelocytic leukemia (HL-60; KCLB 10240) cells, and human neuroblastoma cells (SH-SY5Y; KCLB 22266) were purchased from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea).

3.7.2. Cell Viability

MDCK, HL-60, and SH-SY5Y cells were cultured in DMEM, RPMI 1640, or MEM, respectively [58], supplemented with heat-inactivated 10% FBS, 100 U/mL Penicillin/Streptomycin solution, and 50 µM 2-ME in a humidified atmosphere at 37 °C with 5% CO2 with media change every 2 days, using 75 cm2 T-flask, and were grown until 80% confluent [58]. Passages were used between 10 and 30. Following trypsinization, MDCK (1 × 104), HL-60 (5 × 104), and SH-SY5Y (5 × 104) cells were seeded in 96-well plates and treated with 1, 3, 10, 30 and 50 µM of each inhibitor. The plates were then incubated for 24 h at 37 °C with 5% CO2, and cell viability was determined by the CCK-8 and by measuring the optical density at 450 nm using a microplate reader (Versa Max, Molecular Devices, Sunnyvale, CA, USA). The cell viability was expressed as % by comparing the absorbance of the sample to that of the control [59]. Statistical differences between groups were analyzed by ANOVA using IBM SPSS statistics 27 and probability values (p-values) less than 0.05 were marked as significant values.

3.8. Docking Simulations of the Compounds with MAO-A and MAO-B

AutoDock Vina was used to simulate docking of the chemicals to MAO-A and MAO-B [47]. The binding sites of the chemicals were selected to the binding pocket of 7-methoxy-1-methyl-9H-beta-carboline (HRM) co-crystallized with hMAO-A (PDB ID: 2Z5X), and the binding pocket of (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione (P1B) co-crystallized with hMAO-B (PDB ID: 4A79). To define these binding pockets, the grid boxes for docking were centered to 40.582, 26.931, and −14.540 for hMAO-A, and 50.730, 157.601, and 30.131 for hMAO-B, with dimensions of 15 × 15 × 15 Å. The following steps were carried out to prepare the chemicals for the docking simulation: creation of 2D structures of the chemicals [60], conversion of the 2D structures into 3D structures [61], and energy minimization using the ChemOffice program (http://www.cambridgesoft.com, 23 February 2021) [61]. Docking simulations of MAO-A and MAO-B with the derivatives were performed using Chimera [62]. Based on the docking results, possible hydrogen bonding interactions were checked with relaxation constraints of 0.6 Å and 20.0° [62]. Amino acids with overlapped volume of van der Waals more than −0.4 Å with any atoms in the chemicals were defined as favorable residues.

3.9. Pharmacokinetic Analysis Using In Silico Method

The pharmacokinetics of the compounds were analyzed using the web tool of SwissADME (http://www.swissadme.ch/, 22 October 2022) for gastrointestinal (GI) absorption, blood–brain barrier (BBB) permeability, P-glycoprotein (P-gp) substrate, and cytochrome P450 inhibition, and skin permeation [63].

4. Conclusions

Thirteen compounds were isolated from the methanolic extract of C. lineata including EtOAc and BuOH fractions, and identified as one flavonol, two flavanones, five isoflavones, two syringaresinols, and three pterocarpans. Compounds medicarpin (8) and homopterocarpin (13) were reversible and competitive inhibitor against hMAO-B (IC50 = 0.45 and 0.72 µM, respectively), with high selectivity (SI = 44.2) and low selectivity (SI = 2.07), respectively. Structurally, the group 3-OH at A-ring of 8 increased hMAO-B inhibitory activity, compared to 3-OCH3 group at the A-ring of 13. In addition, 9-OCH3 group at the B-ring of 8 and 13 showed higher MAO-B inhibition than 8,9-methylenedioxy group at the B-ring of 12. Compounds 8 and 13 were non- or less toxic to the normal and cancer cells, including neuroblastoma cells. Molecular docking simulation revealed that 8 or 13 both bonded to Cys172 of hMAO-B with a binding affinity of −8.7 and −7.7 kcal/mol, respectively. However, compound 12 was not predicted to have hydrogen bond to MAO-B. These findings suggest that compounds 8 and 13, a novel potent and reversible hMAO-B inhibitor, should be considered potential candidate agents for the treatment of neurological disorders.

Supplementary Materials

The followings are available online at https://www.mdpi.com/article/10.3390/molecules28010258/s1. Figure S1: Separation scheme of compounds; Figure S2: MS and UV chromatogram of C. lineata pod extract using UPLC-QTOF-MS; Figures S3–S15: UPLC-QTOF-MS spectra of compounds; Figure S16: IC50 curve of compound 8 for hMAO-B; Figure S17: IC50 curves of compound 13 for hMAO-A and hMAO-B.

Author Contributions

Biological activity: J.M.O.; Isolation and identification of the compounds: H.-J.J., S.-J.H., M.H.K. and S.-Y.K.; Docking analysis: M.-G.K. and D.P., Cytotoxicity: S.-K.M. and S.-T.Y.; Pharmacokinetic analysis: J.M.O.; Writing—original draft preparation: J.M.O., H.-J.J. and D.P.; Writing—review and editing: H.K.; Supervision: H.K. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2022R1A2B5B01002536), a KRIBB Research Initiative Program, and the Korea Institute of Toxicology (KIT) Research Program (No. 1711159817).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds used in this study are available from the authors.

References

  1. Barbosa, A.F.; Voos, M.C.; Chen, J.; Francato, D.C.V.; Souza, C.D.O.; Barbosa, E.R.; Chien, H.F.; Mansur, L.L. Cognitive or Cognitive-Motor Executive Function Tasks? Evaluating Verbal Fluency Measures in People with Parkinson’s Disease. BioMed Res. Int. 2017, 2017, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Marino, B.; de Souza, L.R.; Sousa, K.; Ferreira, J.V.; Padilha, E.C.; da Silva, C.; Taft, C.A.; Hage-Melim, L. Parkinson’s disease: A review from pathophysiology to treatment. Mini Rev. Med. Chem. 2020, 20, 754–767. [Google Scholar] [CrossRef] [PubMed]
  3. Masato, A.; Plotegher, N.; Boassa, D.; Bubacco, L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol. Neurodegener. 2019, 14, 35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Khan, S.; Barve, K.H.; Kumar, M.S. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease. Curr. Neuropharmacol. 2020, 18, 1106–1125. [Google Scholar] [CrossRef] [PubMed]
  5. Cao, Z.; Song, Q.; Yu, G.; Liu, Z.; Cong, S.; Tan, Z.; Deng, Y. Novel 3-benzylidene/benzylphthalide mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. 2021, 35, 116074. [Google Scholar] [CrossRef]
  6. Behl, T.; Kaur, D.; Sehgal, A.; Singh, S.; Sharma, N.; Zengin, G.; Andronie-Cioara, F.L.; Toma, M.M.; Bungau, S.; Bumbu, A.G. Role of monoamine oxidase activity in Alzheimer’s disease: An insight into the therapeutic potential of inhibitors. Molecules 2021, 26, 3724. [Google Scholar] [CrossRef]
  7. Al Mamun, A.; Uddin, M.S. KDS2010: A potent highly selective and reversible MAO-B inhibitor for Alzheimer’s disease. Comb. Chem. High. Throughput. Screen. 2020, 23, 836–841. [Google Scholar] [CrossRef]
  8. Hampel, H.; Vassar, R.; De Strooper, B.; Hardy, J.; Willem, M.; Singh, N.; Zhou, J.; Yan, R.; Vanmechelen, E.; De Vos, A.; et al. The β-secretase BACE1 in Alzheimer’s disease. Biol. Psychiatry 2021, 89, 745–756. [Google Scholar] [CrossRef]
  9. Ali, S.; Asad, M.; Maity, S.; Zada, W.; Rizvanov, A.A.; Iqbal, J.; Babak, B.; Hussain, I. Fluoro-benzimidazole derivatives to cure Alzheimer’s disease: In-silico studies, synthesis, structure-activity relationship and in vivo evaluation for β secretase enzyme inhibition. Bioorg. Chem. 2019, 88, 102936. [Google Scholar] [CrossRef]
  10. Ramsay, R.R.; Albreht, A. Kinetics, mechanism, and inhibition of monoamine oxidase. J. Neural Transm. 2018, 125, 1659–1683. [Google Scholar] [CrossRef]
  11. Özdemir, Z.; Alagöz, M.A.; Bahçecioğlu, Ö.F.; Gök, S. Monoamine oxidase-B (MAO-B) inhibitors in the treatment of Alzheimer’s and Parkinson’s disease. Curr. Med. Chem. 2021, 28, 6045–6065. [Google Scholar] [CrossRef] [PubMed]
  12. Finberg, J.P.; Youdim, M.B. Selective MAO A and B inhibitors: Their mechanism of action and pharmacology. Neuropharmacology 1983, 22, 441–446. [Google Scholar] [CrossRef] [PubMed]
  13. Schedin-Weiss, S.; Inoue, M.; Hromadkova, L.; Teranishi, Y.; Yamamoto, N.G.; Wiehager, B.; Bogdanovic, N.; Winblad, B.; Sandebring-Matton, A.; Frykman, S.; et al. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels. Alzheimers Res. Ther. 2017, 9, 57. [Google Scholar] [CrossRef] [Green Version]
  14. Youdim, M.B.H. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J. Neural Transm. 2018, 125, 1719–1733. [Google Scholar] [CrossRef] [PubMed]
  15. Carradori, S.; D’Ascenzio, M.; Chimenti, P.; Secci, D.; Bolasco, A. Selective MAO-B inhibitors: A lesson from natural products. Mol. Divers. 2014, 18, 219–243. [Google Scholar] [CrossRef]
  16. Tripathi, R.K.P.; Ayyannan, S.R. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update. Med. Res. Rev. 2019, 39, 1603–1706. [Google Scholar] [CrossRef]
  17. Guglielmi, P.; Carradori, S.; Ammazzalorso, A.; Secci, D. Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: Is there room for improvement? Expert Opin. Drug Discov. 2019, 14, 995–1035. [Google Scholar] [CrossRef]
  18. Chavarria, D.; Fernandes, C.; Silva, V.; Silva, C.; Gil-Martins, E.; Soares, P.; Silva, T.; Silva, R.; Remião, F.; Oliveira, P.J.; et al. Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies. Eur. J. Med. Chem. 2020, 185, 111770. [Google Scholar] [CrossRef]
  19. Subaraja, M.; Vanisree, A.J. The novel phytocomponent asiaticoside-D isolated from Centella asiatica exhibits monoamine oxidase-B inhibiting potential in the rotenone degenerated cerebral ganglions of Lumbricus terrestris. Phytomedicine 2019, 58, 152833. [Google Scholar] [CrossRef]
  20. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharm. Res. 2013, 36, 375–399. [Google Scholar] [CrossRef]
  21. Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nature reviews. Neuroscience 2003, 4, 131–138. [Google Scholar] [PubMed]
  22. Mesulam, M.; Guillozet, A.; Shaw, P.; Quinn, B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol. Dis. 2002, 9, 88–93. [Google Scholar] [CrossRef] [Green Version]
  23. Darvesh, S. Butyrylcholinesterase as a diagnostic and therapeutic target for Alzheimer’s disease. Curr. Alzheimer Res. 2006, 13, 1173–1177. [Google Scholar] [CrossRef]
  24. Moussa-Pacha, N.M.; Abdin, S.M.; Omar, H.A.; Alniss, H.; Al-Tel, T.H. BACE1 inhibitors: Current status and future directions in treating Alzheimer’s disease. Med. Res. Rev. 2020, 40, 339–384. [Google Scholar] [CrossRef] [PubMed]
  25. Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016, 537, 50–56. [Google Scholar] [CrossRef] [PubMed]
  26. Ibrahim, M.M.; Gabr, M.T. Multitarget therapeutic strategies for Alzheimer’s disease. Neural. Regen. Res. 2019, 14, 437–440. [Google Scholar]
  27. Chowdhury, S.; Kumar, S. Inhibition of BACE1, MAO-B, cholinesterase enzymes, and anti-amyloidogenic potential of selected natural phytoconstituents: Multi-target-directed ligand approach. J. Food Biochem. 2021, 45, e13571. [Google Scholar] [CrossRef]
  28. Ramsay, R.R.; Tipton, K.F. Assessment of enzyme inhibition: A review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs. Molecules 2017, 22, 1192. [Google Scholar] [CrossRef] [Green Version]
  29. Mathew, B.; Parambi, D.G.T.; Mathew, G.E.; Uddin, M.S.; Inasu, S.T.; Kim, H.; Marathakam, A.; Unnikrishnan, M.K.; Carradori, S. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer’s and Parkinson’s diseases. Arch. Pharm. 2019, 352, e1900177. [Google Scholar] [CrossRef]
  30. Baek, S.C.; Park, M.H.; Ryu, H.W.; Lee, J.P.; Kang, M.-G.; Park, D.; Park, C.M.; Oh, S.-R.; Kim, H. Rhamnocitrin isolated from Prunus padus var. seoulensis: A potent and selective reversible inhibitor of human monoamine oxidase A. Bioorg. Chem. 2019, 83, 317–325. [Google Scholar]
  31. Oh, J.M.; Jang, H.-J.; Kim, W.J.; Kang, M.-G.; Baek, S.C.; Lee, J.P.; Park, D.; Oh, S.-R.; Kim, H. Calycosin and 8-O-methylretusin isolated from Maackia amurensis as potent and selective reversible inhibitors of human monoamine oxidase-B. Int. J. Biol. Macromol. 2020, 151, 441–448. [Google Scholar] [CrossRef]
  32. Oh, J.M.; Jang, H.J.; Kang, M.G.; Song, S.; Kim, D.Y.; Kim, J.H.; Noh, J.I.; Park, J.E.; Park, D.; Yee, S.T.; et al. Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii. Sci. Rep. 2021, 11, 13953. [Google Scholar] [CrossRef] [PubMed]
  33. Bu, H.-J.; Lee, H.-J.; Yoo, E.-S.; Jung, D.-S.; Riu, K.-Z.; Lee, S.-J. Antioxidant effects and inhibitory effect on NO synthesis by extracts of Canavalia lineata. Korean J. Pharmacogn. 2004, 35, 338–345. [Google Scholar]
  34. Hong, S.-J.; Kwon, O.-K.; Hwang, D.; Goo, S.H.; Kim, D.-Y.; Kim, M.H.; Kim, S.-Y.; Jang, H.-J.; Oh, S.-R. Anti-inflammatory activity of Cajanin, an isoflavonoid derivative isolated from Canavalia lineata pods. Int. J. Mol. Sci. 2022, 23, 9492. [Google Scholar] [CrossRef] [PubMed]
  35. Terada, S.; Fujimura, S.; Kino, S.; Kimoto, E. Purification and characterization of three proteinase inhibitors from Canavalia lineata seeds. Biosci. Biotechnol. Biochem. 1994, 58, 371–375. [Google Scholar] [CrossRef]
  36. Lee, H.W.; Ryu, H.W.; Kang, M.-G.; Park, D.; Oh, S.-R.; Kim, H. Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens. Bioorg. Med. Chem. Lett. 2016, 26, 4714–4719. [Google Scholar] [CrossRef]
  37. Lee, H.W.; Ryu, H.W.; Baek, S.C.; Kang, M.-G.; Park, D.; Han, H.-Y.; An, J.H.; Oh, S.-R.; Kim, H. Potent inhibitions of monoamine oxidase A and B by acacetin and its 7-O-(6-O-malonylglucoside) derivative from Agastache rugosa. Int. J. Biol. Macromol. 2017, 104, 547–553. [Google Scholar] [CrossRef]
  38. Chaurasiya, N.D.; Zhao, J.; Pandey, P.; Doerksen, R.J.; Muhammad, I.; Tekwani, B.L. Selective inhibition of human monoamine oxidase B by acacetin 7-methyl ether isolated from Turnera diffusa (Damiana). Molecules 2019, 24, 810. [Google Scholar] [CrossRef] [Green Version]
  39. Larit, F.; Elokely, K.M.; Chaurasiya, N.D.; Benyahia, S.; Nael, M.A.; León, F.; Abu-Darwish, M.S.; Efferth, T.; Wang, Y.-H.; Belouahem-Abed, D.; et al. Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants. Phytomedicine 2018, 40, 27–36. [Google Scholar] [CrossRef]
  40. Li, D.; Cai, C.; Liao, Y.; Wu, Q.; Ke, H.; Guo, P.; Wang, Q.; Ding, B.; Fang, J.; Fang, S. Systems pharmacology approach uncovers the therapeutic mechanism of medicarpin against scopolamine-induced memory loss. Phytomedicine 2021, 91, 153662. [Google Scholar] [CrossRef]
  41. Kim, J.H.; Kang, D.M.; Cho, Y.J.; Hyun, J.W.; Ahn, M.J. Medicarpin increases antioxidant genes by inducing NRF2 transcriptional level in HeLa cells. Antioxidants 2022, 11, 421. [Google Scholar] [CrossRef] [PubMed]
  42. Wang, Y.; Yang, R.; Yan, F.; Jin, Y.; Liu, X.; Wang, T. Medicarpin protects cerebral microvascular endothelial cells against oxygen-glucose deprivation/reoxygenation-induced injury via the PI3K/Akt/FoxO pathway: A study of network pharmacology analysis and experimental validation. Neurochem. Res. 2022, 47, 347–357. [Google Scholar] [CrossRef] [PubMed]
  43. Gatouillat, G.; Magid, A.A.; Bertin, E.; El Btaouri, H.; Morjani, H.; Lavaud, C.; Madoulet, C. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells. Phytomedicine 2015, 22, 1186–1194. [Google Scholar] [CrossRef] [PubMed]
  44. Militão, G.C.; Dantas, I.N.; Pessoa, C.; Falcão, M.J.; Silveira, E.R.; Lima, M.A.; Curi, R.; Lima, T.; Moraes, M.O.; Costa-Lotufo, L.V. Induction of apoptosis by pterocarpans from Platymiscium floribundum in HL-60 human leukemia cells. Life Sci. 2006, 78, 2409–2417. [Google Scholar] [CrossRef]
  45. Akinmoladun, A.C.; Olaleye, M.T.; Komolafe, K.; Adetuyi, A.O.; Akindahunsi, A.A. Effect of homopterocarpin, an isoflavonoid from Pterocarpus erinaceus, on indices of liver injury and oxidative stress in acetaminophen-provoked hepatotoxicity. J. Basic Clin. Physiol. Pharmacol. 2015, 26, 555–562. [Google Scholar] [CrossRef]
  46. Mathew, B.; Baek, S.C.; Thomas Parambi, D.G.; Lee, J.P.; Mathew, G.E.; Jayanthi, S.; Vinod, D.; Rapheal, C.; Devikrishna, V.; Kondarath, S.S.; et al. Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole. Arch. Pharm. 2019, 352, e1800309. [Google Scholar] [CrossRef]
  47. Mathew, G.E.; Oh, J.M.; Mohan, K.; Kumudhavalli, M.V.; Jayanthi, S.; Kim, H. Inhibitions of monoamine oxidases and acetylcholinesterase by 1-mehtyl, 5-phenyl substituted thiosemicarbazones: Synthesis, biochemical, and computational investigations. Process Biochem. 2020, 99, 246–253. [Google Scholar] [CrossRef]
  48. Ramsay, R.R.; Majekova, M.; Medina, M.; Valoti, M. Key targets for multi-target ligands designed to combat neurodegeneration. Front. Neurosci. 2016, 10, 375. [Google Scholar] [CrossRef] [Green Version]
  49. Oh, J.M.; Kang, M.-G.; Hong, A.; Park, J.-E.; Kim, S.H.; Lee, J.P.; Baek, S.C.; Park, D.; Nam, S.-J.; Cho, M.-L.; et al. Potent and selective inhibition of human monoamine oxidase-B by 4-dimethylaminochalcone and selected chalcone derivatives. Int. J. Biol. Macromol. 2019, 137, 426–432. [Google Scholar] [CrossRef]
  50. Flockhart, D.A. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine, 2007. Available online: http://medicine.iupui.edu/flockhart/table.htm (accessed on 22 September 2008).
  51. Jang, H.-J.; Kim, W.J.; Lee, S.U.; Kim, M.-O.; Park, M.H.; Song, S.; Kim, D.-Y.; Lee, S.M.; Yuk, H.J.; Lee, D.Y.; et al. Optimization of chiisanoside and chiisanogenin isolation from Eleutherococcus sessiliflorus (Rupr. & Maxim.) leaves for industrial application: A pilot study. Ind. Crops Prod. 2022, 185, 115099. [Google Scholar]
  52. Baek, S.C.; Lee, H.W.; Ryu, H.W.; Kang, M.-G.; Park, D.; Kim, S.H.; Cho, M.-L.; Oh, S.-R.; Kim, H. Selective inhibition of monoamine oxidase A by hispidol. Bioorg. Med. Chem. Lett. 2018, 28, 584–588. [Google Scholar] [CrossRef] [PubMed]
  53. Baek, S.C.; Choi, B.; Nam, S.-J.; Kim, H. Inhibition of monoamine oxidase A and B by demethoxycurcumin and bisdemethoxycurcumin. J. Appl. Biol. Chem. 2018, 61, 187–190. [Google Scholar] [CrossRef]
  54. Baek, S.C.; Ryu, H.W.; Kang, M.-G.; Lee, H.; Park, D.; Cho, M.-L.; Oh, S.-R.; Kim, H. Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid. Bioorg. Med. Chem. Lett. 2018, 28, 2403–2407. [Google Scholar] [CrossRef] [PubMed]
  55. Ellman, G.L.; Courtney, K.D.; Andres, V.; Feather-Stone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–95. [Google Scholar] [CrossRef]
  56. Lee, J.P.; Kang, M.-G.; Lee, J.Y.; Oh, J.M.; Baek, S.C.; Leem, H.H.; Park, D.; Cho, M.-L.; Kim, H. Potent inhibition of acetylcholinesterase by sargachromanol I from Sargassum siliquastrum and by selected natural compounds. Bioorg. Chem. 2019, 89, 103043. [Google Scholar] [CrossRef] [PubMed]
  57. Jeong, G.S.; Kang, M.-G.; Lee, J.Y.; Lee, S.R.; Park, D.; Cho, M.; Kim, H. Inhibition of butyrylcholinesterase and human monoamine oxidase-B by the coumarin glycyrol and liquiritigenin isolated from Glycyrrhiza uralensis. Molecules 2020, 25, 3896. [Google Scholar] [CrossRef]
  58. Noh, J.-I.; Mun, S.-K.; Lim, E.H.; Kim, H.; Chang, D.-J.; Hur, J.-S.; Yee, T. Induction of apoptosis in MDA-MB-231 cells treated with the methanol extract of lichen Physconia hokkaidensis. J. Fungi. 2021, 7, 188. [Google Scholar] [CrossRef]
  59. Park, J.E.; Mun, S.-K.; Yee, S.-T.; Kim, H. Evaluation of inhibitory activities of Sophora flavescens and Angelica gigas Nakai root extracts against monoamine oxidases, cholinesterases, and β-Secretase. Processes 2022, 10, 880. [Google Scholar] [CrossRef]
  60. Trott, O.; Olson, A.J. Auto Dock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar]
  61. Mills, J.E.; Dean, P.M. Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J. Comput. Aided Mol. Des. 1996, 10, 607–622. [Google Scholar] [CrossRef]
  62. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Heo, J.H.; Eom, B.H.; Ryu, H.W.; Kang, M.G.; Park, J.E.; Kim, D.Y.; Kim, J.H.; Park, D.; Oh, S.R.; Kim, H. Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg. Sci. Rep. 2020, 10, 21695. [Google Scholar] [CrossRef] [PubMed]
Molecules 28 00258 g001 550
Figure 1. Chemical structures of compounds 1–13 isolated from the Canavalia lineata; rutin (1), (2R,3R)-3-hydroxy-7-O-d-glucopyranoside-6-methoxy-flavanone (2), (–)-syringaresinol-4-O-β-d-glucopyranoside (3), ononin (4), syringaresinol (5), (2R,3R)-3,7′-dihydroxy-6-methoxy-flavanone (6), cajanin (7), medicarpin (8), prunetin (9), 7,4′-dimethyl-3′-hydroxygenistein (10), 7,4′-dimethoxyisoflavone (11), pterocarpin (12), and homopterocarpin (13).
Figure 1. Chemical structures of compounds 1–13 isolated from the Canavalia lineata; rutin (1), (2R,3R)-3-hydroxy-7-O-d-glucopyranoside-6-methoxy-flavanone (2), (–)-syringaresinol-4-O-β-d-glucopyranoside (3), ononin (4), syringaresinol (5), (2R,3R)-3,7′-dihydroxy-6-methoxy-flavanone (6), cajanin (7), medicarpin (8), prunetin (9), 7,4′-dimethyl-3′-hydroxygenistein (10), 7,4′-dimethoxyisoflavone (11), pterocarpin (12), and homopterocarpin (13).
Molecules 28 00258 g001
Molecules 28 00258 g002 550
Figure 2. SAR analysis of pterocarpans for hMAO-A and hMAO-B inhibitions. Data of maackiain and HMMDP were from a reference [36]. HMMDP, 4-Hydroxy-3-methoxy-8,9-methylenedioxypterocarpan.
Figure 2. SAR analysis of pterocarpans for hMAO-A and hMAO-B inhibitions. Data of maackiain and HMMDP were from a reference [36]. HMMDP, 4-Hydroxy-3-methoxy-8,9-methylenedioxypterocarpan.
Molecules 28 00258 g002
Molecules 28 00258 g003 550
Figure 3. Recovery of hMAO-A inhibition by 13 after dialysis. Toloxatone and clorgyline were used as reference reversible and irreversible MAO-A inhibitors, respectively. The concentrations of the inhibitors used were as follows: 13, 3.0 µM; toloxatone, 2.16 µM; and clorgyline, 0.014 µM. Results are the averages of experiments performed in duplicate.
Figure 3. Recovery of hMAO-A inhibition by 13 after dialysis. Toloxatone and clorgyline were used as reference reversible and irreversible MAO-A inhibitors, respectively. The concentrations of the inhibitors used were as follows: 13, 3.0 µM; toloxatone, 2.16 µM; and clorgyline, 0.014 µM. Results are the averages of experiments performed in duplicate.
Molecules 28 00258 g003
Molecules 28 00258 g004 550
Figure 4. Recoveries of hMAO-B inhibitions by 8 and 13 after dialysis. Lazabemide and pargyline were used as reference reversible and irreversible MAO-B inhibitors, respectively. The concentrations of the inhibitors used were as follows: 8 and 13, 0.90 and 1.44 µM, respectively; lazabemide, 0.22 µM; and pargyline, 0.28 µM. Results are the averages of experiments performed in duplicate.
Figure 4. Recoveries of hMAO-B inhibitions by 8 and 13 after dialysis. Lazabemide and pargyline were used as reference reversible and irreversible MAO-B inhibitors, respectively. The concentrations of the inhibitors used were as follows: 8 and 13, 0.90 and 1.44 µM, respectively; lazabemide, 0.22 µM; and pargyline, 0.28 µM. Results are the averages of experiments performed in duplicate.
Molecules 28 00258 g004
Molecules 28 00258 g005 550
Figure 5. Lineweaver-Burk plots of hMAO-B inhibitions by 8 and their respective secondary plots (A,B) of slopes of Lineweaver–Burk plots versus inhibitor concentrations. Substrate concentrations ranged from 0.03 to 0.6 mM. Experiments were carried out at three inhibitor concentrations, that is, ~0.5, 1.0, and 2.0 times IC50 values. Initial velocity was expressed as an increase in absorbance per min.
Figure 5. Lineweaver-Burk plots of hMAO-B inhibitions by 8 and their respective secondary plots (A,B) of slopes of Lineweaver–Burk plots versus inhibitor concentrations. Substrate concentrations ranged from 0.03 to 0.6 mM. Experiments were carried out at three inhibitor concentrations, that is, ~0.5, 1.0, and 2.0 times IC50 values. Initial velocity was expressed as an increase in absorbance per min.
Molecules 28 00258 g005
Molecules 28 00258 g006 550
Figure 6. Lineweaver-Burk plots of hMAO-A and hMAO-B inhibitions by 13 (A and C, respectively) and their respective secondary plots (B,D) of slopes of Lineweaver-Burk plots versus inhibitor concentrations. Substrate hMAO-A and hMAO-B concentrations ranged from 0.0075 to 0.12, 0.03 to 0.6 mM, respectively. Experiments were carried out at three inhibitor concentrations, that is, ~0.5, 1.0, and 2.0 times IC50 values. Initial velocity was expressed as an increase in absorbance per min.
Figure 6. Lineweaver-Burk plots of hMAO-A and hMAO-B inhibitions by 13 (A and C, respectively) and their respective secondary plots (B,D) of slopes of Lineweaver-Burk plots versus inhibitor concentrations. Substrate hMAO-A and hMAO-B concentrations ranged from 0.0075 to 0.12, 0.03 to 0.6 mM, respectively. Experiments were carried out at three inhibitor concentrations, that is, ~0.5, 1.0, and 2.0 times IC50 values. Initial velocity was expressed as an increase in absorbance per min.
Molecules 28 00258 g006
Molecules 28 00258 g007 550
Figure 7. Effects of 8 and 13 on the viabilities of MDCK (A), HL-60 (B), and SH-SY5Y (C) cells. All cell lines were treated with the compounds (at 1, 3, 10, 30, or 50 µM) for 24 h. Culture supernatants were removed and CCK-8 was added for assay. Data are expressed as the means ± SDs of triplicate experiment. * p < 0.05, *** p < 0.001 compared to the control of each cell. C, control.
Figure 7. Effects of 8 and 13 on the viabilities of MDCK (A), HL-60 (B), and SH-SY5Y (C) cells. All cell lines were treated with the compounds (at 1, 3, 10, 30, or 50 µM) for 24 h. Culture supernatants were removed and CCK-8 was added for assay. Data are expressed as the means ± SDs of triplicate experiment. * p < 0.05, *** p < 0.001 compared to the control of each cell. C, control.
Molecules 28 00258 g007
Molecules 28 00258 g008a 550Molecules 28 00258 g008b 550
Figure 8. Docking simulations of 8 with hMAO-A (2Z5X) (A) and hMAO-B (4A79) (B), 12 with hMAO-A (C) and hMAO-B (D) and 13 with hMAO-A (E) and hMAO-B (F) as determined by AutoDock Vina. Green bars represent hydrogen bonds.
Figure 8. Docking simulations of 8 with hMAO-A (2Z5X) (A) and hMAO-B (4A79) (B), 12 with hMAO-A (C) and hMAO-B (D) and 13 with hMAO-A (E) and hMAO-B (F) as determined by AutoDock Vina. Green bars represent hydrogen bonds.
Molecules 28 00258 g008aMolecules 28 00258 g008b
Table
Table 1. Inhibitions of hMAO-A, hMAO-B, AChE, BChE, and BACE1 by the MeOH extract of C. lineata pods and its EtOAc and BuOH fractions a.
Table 1. Inhibitions of hMAO-A, hMAO-B, AChE, BChE, and BACE1 by the MeOH extract of C. lineata pods and its EtOAc and BuOH fractions a.
Extract/FractionResidual Activity at 25 µg/mL (%)
hMAO-AhMAO-BAChEBChEBACE1
MeOH76.1 ± 3.0753.5 ± 8.6078.2 ± 3.0198.9 ± 0.5076.1 ± 3.07
EtOAc60.9 ± 1.5441.4 ± 2.8664.9 ± 0.7599.6 ± 0.5060.9 ± 1.54
BuOH90.8 ± 0.7785.9 ± 1.4372.9 ± 5.2797.9 ± 1.0090.8 ± 0.77
a Results are expressed as the means ± SDs of two or three experiments.
Table
Table 2. Inhibitions of hMAO-A, hMAO-B, AChE, BChE, and BACE1 by the 13 compounds isolated from C. lineata pod extracts a.
Table 2. Inhibitions of hMAO-A, hMAO-B, AChE, BChE, and BACE1 by the 13 compounds isolated from C. lineata pod extracts a.
CompoundResidual Activity at 10 µM (%)IC50 (µM)SI b
hMAO-AhMAO-BAChEBChEBACE1hMAO-AhMAO-B
196.79 ± 1.5275.22 ± 6.7692.4 ± 7.1699.2 ± 0.8882.56 ± 3.77>40>40-
298.28 ± 2.0169.57 ± 2.4684.8 ± 0.0097.5 ± 0.42163.67 ± 2.96>40>40-
380.00 ± 2.0293.63 ± 3.4795.22 ± 0.0898.91 ± 1.5476.68 ± 4.92>40>40-
498.28± 1.6463.48 ± 1.2386.1 ± 1.7996.7 ± 1.6885.90 ± 0.08>4028.5 ± 1.55>1.40
580.36 ± 6.5763.24 ± 6.2484.49 ± 0.7599.41 ± 0.8381.70 ± 4.01>4024.32 ± 2.20>1.64
694.83 ± 1.9094.64 ± 4.2184.3 ± 1.3191.8 ± 1.3595.72 ± 0.86>40>40-
756.90 ± 0.9231.55 ± 4.2170.8 ± 7.2086.9 ± 2.1183.25 ± 0.4513.1 ± 0.235.18 ± 0.112.53
864.18 ± 0.534.17 ± 0.8480.6 ± 2.6298.4 ± 1.00111.42 ± 0.5219.9 ± 0.850.45 ± 0.03244.2
924.75 ± 1.2230.81 ± 0.8283.2 ± 4.7693.0 ± 0.6587.73 ± 0.592.49 ± 0.325.18 ± 0.0590.48
1041.02 ± 1.0916.86 ± 2.4778.4 ± 3.4098.1 ± 1.9878.86 ± 0.568.05 ± 0.103.47 ± 0.0552.32
1149.15 ± 2.2562.02 ± 1.0982.7 ± 5.4498.7 ± 0.6691.96 ± 0.599.80 ± 0.2713.7 ± 0.100.72
1260.34 ± 0.9013.01 ± 0.7284.9 ± 0.6193.6 ± 2.11102.36 ± 0.4012.5 ± 0.333.36 ± 0.0903.72
1311.59 ± 2.604.05 ± 1.9181.0 ± 2.4488.5 ± 1.96101.48 ± 0.011.49 ± 0.0210.72 ± 0.0282.07
Toloxatone ---1.080 ± 0.025-
Lazabemide ----0.110 ± 0.016
Clorgyline ---0.007 ± 0.001-
Pargyline ----0.140 ± 0.006
Tacrine * 0.270 ± 0.0190.060 ± 0.0022---
Donepezil * 0.010 ± 0.0020.180 ± 0.0038---
Quercetin * --13.420 ± 0.035--
Inhibitor IV * 0.440 ± 0.064
a Results are expressed as the means ± SDs of two or three experiments. b SI values for hMAO-B selectivity were calculated by dividing IC50 values of hMAO-A by those of hMAO-B. * Values were represented as IC50 values of reference compounds against AChE, BChE, and BACE1.
Table
Table 3. Docking scores and predicted hydrogen bond(s) of the three compounds with hMAO-A or hMAO-B *.
Table 3. Docking scores and predicted hydrogen bond(s) of the three compounds with hMAO-A or hMAO-B *.
CompoundDocking Energy (kcal/mol)H-Bond Predicted
hMAO-AhMAO-BhMAO-AhMAO-B
8−3.4−8.7 Cys172 (3.328 Å)
12−2.4−7.5
13−7.1−7.7Tyr444 (3.588 Å)Cys172 (3.333 Å)
* Determined by AutoDock Vina.
Table
Table 4. Pharmacokinetic properties of medicarpin and homopterocarpin.
Table 4. Pharmacokinetic properties of medicarpin and homopterocarpin.
CompoundGI
Absorption		BBB
Permeant		P-gp SubstrateInhibitorLog Kp
CYP1A2CYP2C19CYP2C9CYP2D6CYP3A4Skin Permeation (cm/s)
8HighYYYYNYY−5.98
13HighYYYYNYY−5.84
GI, gastrointestinal; BBB, blood–brain barrier; P-gp, P-glycoprotein.
Table
Table 5. Physicochemical parameters and Lipinski violations.
Table 5. Physicochemical parameters and Lipinski violations.
CompoundMw (g/mol)cLog PHBDHBATPSA (Å2)RBLipinski Violations
8270.282.531447.9210
13284.312.910436.9220
Mw, molecular weight; cLog P, consensus Log P, HBD: H-bond donors; HBA, H-bond acceptors; TPSA, topological polar surface area; RB, rotatable bonds.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Oh, J.M.; Jang, H.-J.; Kang, M.-G.; Mun, S.-K.; Park, D.; Hong, S.-J.; Kim, M.H.; Kim, S.-Y.; Yee, S.-T.; Kim, H. Medicarpin and Homopterocarpin Isolated from Canavalia lineata as Potent and Competitive Reversible Inhibitors of Human Monoamine Oxidase-B. Molecules 2023, 28, 258. https://doi.org/10.3390/molecules28010258

AMA Style

Oh JM, Jang H-J, Kang M-G, Mun S-K, Park D, Hong S-J, Kim MH, Kim S-Y, Yee S-T, Kim H. Medicarpin and Homopterocarpin Isolated from Canavalia lineata as Potent and Competitive Reversible Inhibitors of Human Monoamine Oxidase-B. Molecules. 2023; 28(1):258. https://doi.org/10.3390/molecules28010258

Chicago/Turabian Style

Oh, Jong Min, Hyun-Jae Jang, Myung-Gyun Kang, Seul-Ki Mun, Daeui Park, Su-Jin Hong, Min Ha Kim, Soo-Young Kim, Sung-Tae Yee, and Hoon Kim. 2023. "Medicarpin and Homopterocarpin Isolated from Canavalia lineata as Potent and Competitive Reversible Inhibitors of Human Monoamine Oxidase-B" Molecules 28, no. 1: 258. https://doi.org/10.3390/molecules28010258

APA Style

Oh, J. M., Jang, H. -J., Kang, M. -G., Mun, S. -K., Park, D., Hong, S. -J., Kim, M. H., Kim, S. -Y., Yee, S. -T., & Kim, H. (2023). Medicarpin and Homopterocarpin Isolated from Canavalia lineata as Potent and Competitive Reversible Inhibitors of Human Monoamine Oxidase-B. Molecules, 28(1), 258. https://doi.org/10.3390/molecules28010258

Article Metrics

Back to TopTop